Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
This page contains historical news coverage for Centogene NV (CNTG), a genetic diagnostics company that specialized in rare hereditary diseases. Centogene was acquired by private equity firm Charme Capital Partners and no longer operates as a publicly traded company. This archive documents the company's history and business developments before its transition to private ownership.
Centogene focused on diagnosing rare genetic disorders through advanced sequencing technologies and maintained a proprietary database of genetic variants linked to clinical outcomes. The company served both individual patients seeking diagnoses and pharmaceutical companies developing treatments for rare conditions.
Browse this historical news archive to understand Centogene's business trajectory, including its pharmaceutical partnerships, diagnostic service expansions, and the events leading to its acquisition. News coverage spans the company's period as a NASDAQ-listed stock, offering context for investors researching the rare disease diagnostics sector or tracking former holdings.
For those researching rare disease diagnostics companies or the genetic testing industry, this archive provides insight into how a specialized diagnostic laboratory operated and partnered with drug developers in this niche healthcare segment.
CENTOGENE has launched its validated COVID-19 test kit, CentoKit-19™, on Amazon in Germany, marking the first of its kind available through the platform. This testing solution aims to enhance access to COVID-19 testing, enabling individuals to receive results efficiently through digital reports. The test is validated according to WHO guidelines and offers a comprehensive at-home testing experience, including all necessary materials for sampling and return. The initiative supports public health efforts to manage the pandemic by facilitating early detection and breaking infection chains.
Centogene N.V. (Nasdaq: CNTG) has announced the pricing of a public offering of 3,500,000 common shares at $14.00 each, aiming to raise $28 million for the company and $21 million for selling shareholders. The offering includes 2,000,000 shares from the company and 1,500,000 shares from shareholders. The underwriters have a 30-day option to purchase an additional 525,000 shares. Proceeds will support research and development for orphan drug initiatives, working capital, and potential acquisitions. The offering is set to close around July 14, 2020.
Centogene N.V. (Nasdaq: CNTG) announced the publication of its paper titled ‘Rapid Large-Scale COVID-19 Testing During Shortages’ in Diagnostics. The study highlights innovative testing solutions amidst the COVID-19 pandemic, contributing valuable insights to the medical community. CEO Prof. Arndt Rolfs emphasized their commitment to high-quality molecular diagnostics, particularly in supporting widespread SARS-CoV-2 testing. The company aims to enhance patient care through reliable testing and has established a testing service at Frankfurt airport, reinforcing its role in addressing public health challenges.
Centogene N.V. (Nasdaq: CNTG) has initiated an underwritten public offering of 3.5 million common shares, consisting of 2 million shares from the company and 1.5 million from selling shareholders, with an additional 525,000 shares available for underwriters. Proceeds from the offering will fund research and development for orphan drug initiatives, working capital, and potential investments in complementary businesses. The offering is dependent on market conditions and a registration statement is pending effectiveness.
Centogene N.V. (Nasdaq: CNTG) has partnered with OESIS Network to provide COVID-19 screening for schools across the U.S. The partnership will utilize RT-PCR testing at affordable prices, aimed at facilitating the safe return of students and staff to campus. Up to 50,000 tests per week will be available, with potential for increased capacity. The initiative emphasizes privacy, utilizing anonymized sample collection. With a focus on quality and logistics, Centogene's services will support both public and independent schools, potentially funded through the Cares Act.
Centogene N.V. (Nasdaq: CNTG) announced that the FDA has granted Emergency Use Authorization for its SARS-CoV-2 RT-PCR test. This test is designed for qualitative detection of the virus using upper respiratory samples. CEO Prof. Arndt Rolfs emphasized the company's commitment to high-quality diagnostics to combat COVID-19. The test, intended for use in CENTOGENE's certified laboratories in Germany, aims to facilitate early diagnosis and support public health initiatives. The company collaborates with pharmaceutical partners to enhance testing efficacy.
CENTOGENE (NASDAQ: CNTG) has partnered exclusively with Lufthansa and Fraport to offer COVID-19 testing for passengers at Frankfurt Airport. This initiative aims to facilitate safe international travel as restrictions ease. The testing service is now available and will continue until July 31, 2021. Passengers can access a convenient walk-in testing center, obtaining results via a secure digital platform, essential for travels to countries requiring testing. This collaboration represents a significant step towards normalizing air travel amid the pandemic.
Centogene N.V. (Nasdaq: CNTG) announced the resignation of Supervisory Board member Christoph Ehlers, effective June 15, 2020, due to personal circumstances. Ehlers served over six years and contributed significantly to the company's growth. CEO Prof. Arndt Rolfs expressed gratitude for Ehlers' role and noted his ongoing involvement. Centogene specializes in rare diseases, leveraging real-world clinical and genetic data to aid patients and pharmaceutical companies, boasting a repository of 3.0 billion weighted data points from over 530,000 patients across 120 countries as of March 31, 2020.
Centogene N.V. (Nasdaq: CNTG) reported €12.1 million in revenues for Q1 2020, marking a 13% increase year-over-year. The company continues expanding its rare disease platform, with approximately 3 billion data points from over 530,000 patients. Despite the challenges posed by COVID-19, Centogene launched its CentoSwab™ testing kit and expanded testing capabilities. However, the company reported a comprehensive loss of €8.6 million, or €0.43 per share, compared to €5.2 million, or €0.33 per share, in Q1 2019. R&D and G&A expenses also increased significantly.
Centogene N.V. (Nasdaq: CNTG) announced it will report its financial results for Q1 2020 on June 15, 2020. The earnings call will take place at 8 a.m. EST, where the company will discuss its financial performance and outlook. Centogene focuses on rare diseases, utilizing a platform that integrates clinical and genetic data from approximately 500,000 patients across 120 countries. The company collaborates with over 39 pharmaceutical partners to enhance orphan drug development. Interested participants can access the call by dialing provided numbers or via the company's Investor Relations webpage.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
